Official Title
A Study for Patients Newly Diagnosed With Glioblastoma Being Treated With Standard Radiotherapy and Temozolomide (TMZ) to Evaluate Tumor Response Via Liquid Biopsies (GRETeL)
Brief Title
GRETeL: Tumor Response to Standard Radiotherapy and TMZ Patients With GBM
Protocol ID
NCT05695976
Lead Sponsor
Duke University
Brief Summary
The purpose of this study is to better define longitudinal genomic alterations in
patients with glioblastoma (GBM), and to determine if plasma circulating tumor DNA
(ctDNA) or cell free DNA (cfDNA) is associated with disease recurrence, survival, tumor
characteristics, and/or peripheral immunosuppression.
Study Period
Enrollment Count
100 participants
Eligibility Criteria
Inclusion Criteria:
- Age ≥ 18 years
- Patients newly diagnosed with malignant glioma, IDH wildtype who have undergone
surgical resection for their tumor and who are planned for standard of care
radiation therapy with concurrent temozolomide (i.e., at least 59 Gy in 30 fractions
over 6 weeks)
- Patients must have leftover tissue available from the surgical resection of their
tumor available to request for this research.
- Able to undergo MRI of brain with and without contrast
- Signed informed consent approved by the Institutional Review Board (IRB)
Exclusion Criteria:
- Prior, unrelated malignancy requiring current active treatment with the exception of
cervical carcinoma in situ and adequately treated basal cell or squamous cell
carcinoma of the skin
Filters
Glioblastoma
Glioma, Malignant
SUSPENDED
ADULT
OLDER_ADULT